Skip to main content

Table 3 DaT-SPECT quantitative metrics

From: Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial

  DaT-SPECT screened DaT-SPECT “abnormal” DaT-SPECT “normal”
Quantifiable, N 389 377 12
Striatal binding ratio
 Whole striatum 1.37 ± 0.37 1.35 ± 0.35 2.03 ± 0.54
 Whole putamen 1.33 ± 0.41 1.30 ± 0.37 2.27 ± 0.61
 Whole caudate 1.40 ± 0.37 1.39 ± 0.36 1.79 ± 0.49
 Most affected putamen 1.19 ± 0.39 1.16 ± 0.33 2.21 ± 0.61
 Demographically indexed most affected putamen 0.25 ± 0.08 0.24 ± 0.07 0.46 ± 0.11
Abnormal whole striatum uptake, % 99.4 100 83
Abnormal whole putamen uptake, % 99.4 98.7 75
Abnormal whole caudate uptake, % 100 100 100
Striatal asymmetry index 4.30 ± 2.85 4.40 ± 2.84 1.17 ± 0.70
Abnormal striatal asymmetry index, % 0 0.5 0
  1. Data are mean ± SD unless otherwise noted
  2. DaT-SPECT dopamine transporter single-photon emission computed tomography